Navigation Links
Delivering Chemo Directly Into Brain Tumors Shows Promise
Date:5/4/2009

Survival times for those with malignant gliomas increased, study found

MONDAY, May 4 (HealthDay News) -- Using a catheter to deliver chemotherapy drugs directly into a deadly type of brain tumor is showing promise in early clinical trials, researchers report.

Malignant gliomas are difficult to treat using standard chemotherapy and radiation treatments. Only about 3 percent of patients diagnosed with a malignant glioma survive five years or more, according to background information in the study.

With the new method, researchers inserted catheters carrying the chemotherapy drug Topotecan (Hycamtin) directly into the tumors of 16 patients with recurrent malignant gliomas.

The patients who received the Topotecan had a median survival of 59 weeks, although a few patients lived much longer. The median time to tumor progression was 20 weeks, and 77 percent of patients survived for at least six months.

"Those numbers are better than any treatment for recurrent gliomas we have now," said study author Dr. Jeffrey Bruce, co-director of the Brain Tumor Center at Columbia University Medical Center in New York City.

Findings from the Phase 1 trial are slated to be presented Monday at the American Association of Neurological Surgeons annual meeting, in San Diego.

Malignant gliomas are typically resistant to treatment for several reasons, explained Dr. Paul Fisher, an associate professor of neurology and pediatrics at Stanford Medical Center and the Beirne Family Director of Neuro-Oncology.

Chemotherapy is typically given orally or intravenously. In brain tumors, chemotherapy is not very effective, because drugs are not able to penetrate the blood-brain barrier, which prevents most drugs in the bloodstream from entering the brain, the researchers wrote.

Malignant gliomas also send out tentacles, making the tumors very difficult to completely remove surgically. Even when there's no tumor visible, microscopic glioma cells usually remain that eventually regrow, Fisher said.

Sen. Edward Kennedy (D-Mass.) is currently battling a malignant glioma.

Topotecan is sold by GlaxoSmithKline and is typically used in lung cancer patients, Bruce said.

In the lab, the drug had been shown to be effective in killing malignant glioma cells, but delivering enough of it through the bloodstream to attack brain tumors would cause too many toxic side effects.

So for four days, using a procedure called convection-enhanced delivery, Topotecan was pumped into tumors in 16 patients through two catheters. The pumping was done very slowly, at a rate of several drops an hour, Bruce said.

Side effects included upper extremity weakness and left parietal syndrome, neurological issues caused by damage to the brain.

The patients had two types of tumors: 10 had a glioblastoma multiforme (GBM), an invasive and fast-growing tumor, while six had anaplastic glioma.

"Topotecan by convection-enhanced delivery has significant anti-tumor effects at doses that are not harmful to normal brain tissue," Bruce said. "These promising preliminary results indicate that this treatment provides a survival advantage that is favorable compared to other treatments that are often used for recurrent malignant gliomas."

The next step will be multi-center Phase 2 clinical trial, which will begin in the next two to three months, Bruce said.

Fisher said the results were encouraging, but the study was limited in that it involved only a small number of patients and two different types of tumors.

"The technology is to be applauded," Fisher said. "We need to be trying new approaches and trying to do things in a different way. Just giving chemotherapy by an IV or radiation is not going to advance the field."

A second study that will also be presented at the conference also explored an alternative method of delivering chemotherapy drugs to malignant gliomas, this time using nanoparticles.

After injecting cancerous glioma cells into immunocompromised mice, researchers injected the mice with controlled-release nanoparticles that were able to carry the chemotherapy drug fluorouracil (Adrucil) to the tumor site.

The University of Virginia researchers then used high-intensity ultrasound to release the agents in the microvessels feeding the tumor.

The chemotherapy drug killed the glioma cells in the mice, the scientists reported.

More information

The U.S. National Library of Medicine has more on malignant glioma.



SOURCES: Jeffrey Bruce, M.D., professor, neurological surgery, and co-director, Brain Tumor Center, Columbia University Medical Center, New York City; Paul Fisher, M.D., associate professor, neurology and pediatrics, Stanford Medical Center and the Beirne Family Director of Neuro-Oncology, Palo Alto, Calif.; May 4, 2009, American Association of Neurological Surgeons annual meeting, San Diego


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions
2. ACORNs Success in Delivering Top Quality Research Portfolio to Community-Based Oncology Practices Presented at Annual Investigator Meeting
3. Delivering Bear-y Big Smiles and Millions of Miles
4. SCAN: Delivering Bone Disorder Diagnosis, Fracture Healing
5. SCAN: Delivering bone disorder diagnosis, fracture healing
6. CVS/pharmacy and MinuteClinic Reach Goal of Delivering One Million Flu Vaccinations
7. Creating Brand Advocates by Delivering the Superior Total Customer Experience
8. Historic Lawsuit Challenges Unacceptable Delays in Delivering Benefits to Americas Veterans by Department of Veterans Affairs
9. International Medical Corps Continues Delivering Emergency Relief in Democratic Republic of Congo as Potential for Renewed Fighting Threatens to Deepen Crisis
10. International Medical Corps Continues Delivering Emergency Relief Amid Violence in Democratic Republic of Congo
11. PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Delivering Chemo Directly Into Brain Tumors Shows Promise
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: